Press Release

August 02, 2021
1 min read

Zanubrutinib extends PFS in treatment-naive CLL


Press Release

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact

Zanubrutinib prolonged PFS compared with bendamustine plus rituximab among patients with treatment-naive chronic lymphocytic leukemia or small lymphocytic lymphoma who did not harbor deletion 17p.

The regimen also appeared well-tolerated, topline data released by the agent’s manufacturer showed.

Blood picture of chronic lymphocytic leukemia or CLL, analyze by microscope, original magnification 1000x
Source: Adobe Stock.

Zanubrutinib (Brukinsa, BeiGene) is a Bruton tyrosine kinase inhibitor approved in the United States for treatment of adults with mantle cell lymphoma who received at least one prior therapy.

The randomized phase 3 SEQUOIA trial evaluated zanubrutinib vs. bendamustine plus rituximab (Rituxan; Genentech, Biogen) for patients with treatment-naive CLL or small lymphocytic lymphoma.

Cohort 1 of the trial included 479 patients who did not harbor deletion 17p.

Researchers randomly assigned these patients to zanubrutinib (n = 241) or bendamustine-rituximab (n = 238). Treatment continued until disease progression or unacceptable toxicity.

PFS assessed by independent review committee served as the primary endpoint. Secondary endpoints included investigator-assessed PFS; independent review committee- and investigator-assessed overall response rate; and other efficacy and safety outcomes.

After median follow-up of 25.8 months, results of an interim analysis showed zanubrutinib-treated patients achieved significantly longer PFS than those who received the chemoimmunotherapy regimen by both independent central review and investigator assessment.

Zanubrutinib also appeared well-tolerated, exhibiting a safety profile consistent with its known profile.

As Healio previously reported, results of the randomized phase 3 ALPINE trial showed zanubrutinib induced a higher overall response rate than ibrutinib (Imbruvica; Janssen, Pharmacyclics) among patients with relapsed or refractory CLL. Zanubrutinib also appeared associated with higher rates of 12-month PFS and OS.

“The combined clinical evidence from SEQUOIA, ALPINE [and other trials] validates our confidence in Brukinsa as a regimen [that] can offer improvements in treatment outcomes for hundreds of thousands of patients living with CLL,” Jane Huang, MD, chief medical officer for hematology with BeiGene, said in a company-issued press release. “We are pleased to see that at the interim analysis of the SEQUOIA trial, Brukinsa significantly prolonged progression-free survival for treatment-naive [patients with CLL], and that the demonstrated safety profile was consistent with what we have observed in its global development program with more than 2,300 patients treated with Brukinsa to date.”